GEFTINAT GEFTINIB TABLETS IP

Get a Price/Quote

MOQ : 1 Strip

GEFTINAT GEFTINIB TABLETS IP Specification

Dosage Form
Tablet

Indication
Non-Small Cell Lung Cancer (NSCLC)

Salt Composition
Gefitinib 250 mg

Enzyme Types
Tyrosine Kinase Inhibitor

Feature
Oral targeted therapy, once-daily dosing

Ingredients
Gefitinib, Excipients

Application
Treatment of locally advanced or metastatic non-small cell lung cancer

Physical Color/Texture
White to off-white, film-coated tablets

Fermentation Smell
Odorless

Enzymatic Activity
Selective inhibition of EGFR tyrosine kinase

Storage Instructions
Store below 30C, protect from moisture and light

Shelf Life
24 months

Therapeutic Class
Antineoplastic agent

Pack Size
30 tablets per bottle

Manufactured By
Natco Pharma Ltd.

Regulatory Status
Approved by DCGI (India)

Prescription Status
Prescription Only

Tablet Markings
Imprinted with dosage strength

Adverse Effects
Rash, diarrhea, nausea, hepatic dysfunction

Interactions
Potential interaction with CYP3A4 inhibitors/inducers

Usage Instructions
As directed by oncologist

Contraindications
Hypersensitivity to Gefitinib

Administration Route
Oral

GEFTINAT GEFTINIB TABLETS IP Trade Information

Minimum Order Quantity
1 Strip

Packaging Details
PACK OF 30 TABLETS

Main Domestic Market
All India

About GEFTINAT GEFTINIB TABLETS IP

Geftinat- Gefitinib

Geftinat contains gefitinib and belongs to a class of anti-cancer medications called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.Geftinat is used for the treatment of non-small cell lung cancer.

Specification :-

Brand name: Geftinat
Contains: Gefitinib
Strength: Geftinat 250 Mg
Packing : 1 Bottle Of Geftinat Contains 30 Tablets
Manufactured By : Natco

Note:Geftinat Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug.

Targeted Therapy for NSCLC

GEFTINAT is designed as an oral tyrosine kinase inhibitor specifically for non-small cell lung cancer, offering a convenient once-daily treatment. Its mechanism directly targets the EGFR protein, reducing tumor growth and improving treatment outcomes compared to conventional chemotherapy. Patients benefit from minimized systemic toxicity and easier administration.

Safe Administration and Usage

Gefitinib tablets should always be taken as prescribed by an oncologist. The oral route allows patients to take their medication at home, reducing hospital visits. Tablets are marked for clear identification, promoting accurate dosing. Patients must adhere strictly to usage instructions for optimum effectiveness and safety.

FAQs of GEFTINAT GEFTINIB TABLETS IP:

Q: How should GEFTINAT Gefitinib Tablets IP be taken for non-small cell lung cancer?

A: These tablets are intended for oral administration and should be taken once daily, exactly as directed by your oncologist. Do not adjust the dosage or discontinue use without consulting healthcare professionals.

Q: What are the main benefits of using GEFTINAT for NSCLC treatment?

A: GEFTINAT offers targeted therapy by selectively inhibiting EGFR tyrosine kinase, frequently resulting in better outcomes and fewer side effects compared to conventional chemotherapy. Its oral form enables convenient at-home administration.

Q: When should GEFTINAT not be used?

A: GEFTINAT is contraindicated in individuals with known hypersensitivity to Gefitinib or any tablet components. Notify your doctor immediately about any previous allergic reactions.

Q: Where should I store GEFTINAT Gefitinib Tablets?

A: These tablets should be kept below 30C, away from moisture and direct light, and securely out of reach of children or pets. Proper storage helps preserve the medications efficacy within its 24-month shelf life.

Q: What adverse effects can GEFTINAT cause and how are they managed?

A: Common adverse effects include rash, diarrhea, nausea, and hepatic dysfunction. Monitoring by your oncologist is essential to manage and address side effects swiftly. Inform your healthcare provider if you experience any unusual symptoms.

Q: How does GEFTINAT interact with other medicines?

A: Gefitinib may interact with drugs affecting CYP3A4 enzyme activity such as inhibitors or inducers, possibly altering its effectiveness or increasing side effects. Share your complete medication list with your oncologist.

Tell us about your requirement